Summary
Immunotherapy is a promising approach to treat cancer and infectious diseases, but innovative approaches are required.
The cGAS-cGAMP-STING pathway can induce a potent immune response against viruses. It is also implicated in antitumoral immune responses that are effective. We have recently discovered that the small second messenger cGAMP can be packaged by viruses to stimulate immunity in target cells. We have developed methods to produce non-infectious virus-like particles containing cGAMP (cGAMP-VLPs) that strongly stimulate this innovative immune pathway. We will test the idea that cGAMP-VLPs are potent activators of anti-tumoral and anti-viral immunity. To reach this proof-of-concept, we
propose pre-clinical development plan in translational mouse models.
The cGAS-cGAMP-STING pathway can induce a potent immune response against viruses. It is also implicated in antitumoral immune responses that are effective. We have recently discovered that the small second messenger cGAMP can be packaged by viruses to stimulate immunity in target cells. We have developed methods to produce non-infectious virus-like particles containing cGAMP (cGAMP-VLPs) that strongly stimulate this innovative immune pathway. We will test the idea that cGAMP-VLPs are potent activators of anti-tumoral and anti-viral immunity. To reach this proof-of-concept, we
propose pre-clinical development plan in translational mouse models.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/727408 |
| Start date: | 01-02-2017 |
| End date: | 31-07-2018 |
| Total budget - Public funding: | 150 000,00 Euro - 150 000,00 Euro |
Cordis data
Original description
Immunotherapy is a promising approach to treat cancer and infectious diseases, but innovative approaches are required.The cGAS-cGAMP-STING pathway can induce a potent immune response against viruses. It is also implicated in antitumoral immune responses that are effective. We have recently discovered that the small second messenger cGAMP can be packaged by viruses to stimulate immunity in target cells. We have developed methods to produce non-infectious virus-like particles containing cGAMP (cGAMP-VLPs) that strongly stimulate this innovative immune pathway. We will test the idea that cGAMP-VLPs are potent activators of anti-tumoral and anti-viral immunity. To reach this proof-of-concept, we
propose pre-clinical development plan in translational mouse models.
Status
CLOSEDCall topic
ERC-PoC-2016Update Date
27-04-2024
Images
No images available.
Geographical location(s)
